```html

Menorrhagia: A Comprehensive Medical Guide

Overview

Menorrhagia (also called heavy menstrual bleeding) is defined as menstrual blood loss exceeding 80 mL per cycle or bleeding that lasts longer than 7 days, regardless of the measured volume. It is one of the most common reasons women seek gynecologic care.

• Who it affects: Typically women of reproductive age (15‑49 years), but it can also occur in adolescents who have recently started menstruating and in perimenopausal women.
• Prevalence: Approximately 20 % of menstruating women report heavy bleeding at some point in their lives. Among those, 5‑10 % experience it severely enough to interfere with daily activities or cause anemia.

Because “heavy” is often a subjective perception, clinicians use a combination of patient history, menstrual charts, and objective tests (e.g., alkaline‑hematin method) to confirm the diagnosis.

Symptoms

Menorrhagia may present alone or alongside other menstrual disorders. Common symptoms include:

• Excessive blood loss – soaking through one or more regular‑size sanitary pads or tampons every hour for several consecutive hours.
• Prolonged periods – bleeding for more than 7 days (normal range is 2‑7 days).
• Clots – passing clots larger than a quarter (≈ 1 cm) in diameter.
• Frequent pad/tampon changes – needing to change pads/tampons every 1‑2 hours.
• Iron‑deficiency anemia symptoms – fatigue, weakness, shortness of breath, pallor, dizziness, or headaches.
• Pelvic pressure or pain – a feeling of heaviness or cramping that may worsen during the heavy phase.
• Impact on quality of life – missed work/school, reduced participation in exercise or social events.
• Other signs – occasional fainting (syncope) during menstruation, especially if blood loss is rapid.

Causes and Risk Factors

Menorrhagia is usually a symptom of an underlying condition rather than a disease itself. The main categories are:

Structural Causes

• Uterine fibroids (leiomyomas) – benign smooth‑muscle tumors; most common cause in women >30 years.
• Endometrial polyps – localized overgrowths of the endometrial lining.
• Adenomyosis – endometrial tissue within the uterine muscle, leading to bulky, heavy bleeding.
• Malignancy – endometrial hyperplasia or cancer (rare but must be excluded in women >45 years with new‑onset bleeding).

Systemic/Medical Causes

• Coagulation disorders – von Willebrand disease, platelet function defects, or use of anticoagulants.
• Hormonal imbalances – anovulatory cycles (common in adolescents and perimenopause) lead to unopposed estrogen.
• Thyroid disorders – hypothyroidism or hyperthyroidism.
• Chronic diseases – liver disease, kidney disease, or inflammatory bowel disease.

Medication‑Related Causes

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – can impair platelet function.
• Hormonal contraceptives (especially progestin‑only methods) – occasional breakthrough bleeding.
• Anticoagulants (warfarin, direct oral anticoagulants) – increase overall bleeding tendency.

Risk Factors

• Age 30‑45 years (peak incidence of fibroids).
• Family history of bleeding disorders or fibroids.
• Obesity – higher estrogen levels from adipose tissue.
• Nulliparity (never given birth) – associated with larger uterine size.
• Use of intrauterine devices (IUDs) that are non‑hormonal (copper IUD) – may increase flow.

Diagnosis

Diagnosis starts with a thorough history and physical exam, followed by targeted investigations.

History & Physical Exam

• Menstrual diary: number of pads/tampons used, duration, presence of clots.
• Assess for anemia symptoms, family bleeding history, medication list.
• Pelvic exam – to detect fibroids, polyps, cervical lesions.

Laboratory Tests

• Complete blood count (CBC) – looks for low hemoglobin/hematocrit.
• Ferritin & iron studies – evaluate iron‑deficiency anemia.
• Coagulation profile – PT/INR, aPTT; if abnormal, refer for hematology.
• Thyroid function tests – TSH, free T4.
• Von Willebrand factor assay – if a bleeding disorder is suspected.

Imaging & Endoscopic Tests

• Transvaginal ultrasound – first‑line imaging for fibroids, polyps, adenomyosis.
• Sonohysterography (saline‑infusion sonography) – more sensitive for intracavitary lesions.
• Magnetic resonance imaging (MRI) – used when ultrasound is inconclusive, especially for adenomyosis.
• Endometrial biopsy – indicated in women >45 years or with risk factors for cancer.
• Hysteroscopy – direct visualization and possible removal of polyps/fibroids.

Quantifying Blood Loss (optional)

Research settings may use the alkaline‑hematin method or the pictorial blood‑assessment chart (PBAC). In routine practice, a PBAC score > 100 is considered consistent with menorrhagia.

Treatment Options

Treatment is individualized based on severity, desire for future fertility, underlying cause, and patient preference. Options fall into three categories: medical therapy, procedural interventions, and lifestyle modifications.

Medical Therapies

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – e.g., ibuprofen 400‑600 mg q6–8 h. Reduce prostaglandin‑mediated uterine bleeding but do not treat underlying pathology.
• Tranexamic acid (TXA) – 1 g orally three times a day for up to 5 days during menstruation. Reduces blood loss by 30‑50 % (FDA‑approved for menorrhagia).
• Hormonal contraceptives
  • Combined oral contraceptive pills (COCP) – cyclic or continuous use suppresses ovulation, stabilizes endometrium.
  • Progestin‑only pills, injectables (depot medroxyprogesterone acetate), or the levonorgestrel intrauterine system (LNG‑IUS, Mirena®) – the LNG‑IUS is especially effective, decreasing bleeding by up to 90 % and may shrink fibroids.
• Gonadotropin‑releasing hormone (GnRH) agonists/antagonists – e.g., leuprolide acetate, elagolix. Induce a hypo‑estrogenic state, shrinking fibroids and reducing bleeding; limited to short‑term use (≤ 6 months) because of bone‑density loss.
• Selective progesterone receptor modulators (SPRMs) – ulipristal acetate (approved in Europe) can control bleeding and reduce fibroid volume.
• Iron supplementation – oral ferrous sulfate 325 mg bid or IV iron sucrose if anemia is moderate‑severe.

Procedural / Surgical Interventions

• First‑line minimally invasive
  • Endometrial ablation (thermal, radiofrequency, hydrothermal). Suitable for women who have completed childbearing; success rate ≈ 80‑90 %.
  • Office hysteroscopic polypectomy or myomectomy for localized lesions.
• Surgical options
  • Myomectomy – removal of fibroids while preserving uterus; indicated for women desiring future fertility.
  • Hysterectomy – definitive cure; considered after failure of conservative measures or when malignancy is suspected. Accounts for ≈ 600,000 procedures annually in the U.S.

Lifestyle & Supportive Measures

• High‑iron diet (red meat, leafy greens, legumes) and vitamin C to enhance absorption.
• Regular aerobic exercise – may reduce menstrual blood loss in some women.
• Stress‑management techniques (yoga, mindfulness) – can improve hormonal balance.

Living with Menorrhagia

Even with treatment, day‑to‑day management is key to maintaining quality of life.

• Track your cycle – use a smartphone app or paper chart to record pad changes, clots, and symptoms. This data helps providers adjust therapy.
• Keep a supply of menstrual products – consider high‑absorbency pads, menstrual cups, or reusable cloth pads. Some women find a combination (e.g., pad + tampon) offers best protection.
• Plan ahead for travel or work – carry a discreet “menstrual kit” with extra products, a spare pair of underwear, and a small bottle of TXA if prescribed.
• Manage anemia – schedule periodic CBC checks (every 3‑6 months) until hemoglobin stabilizes above 12 g/dL.
• Stay hydrated and maintain a balanced diet – dehydration can exacerbate cramps.
• Discuss fertility goals early – some treatments (e.g., LNG‑IUS, endometrial ablation) are not reversible.
• Seek psychosocial support – heavy bleeding can cause anxiety or depression. Talk therapy or support groups may be beneficial.

Prevention

Because many causes are not fully controllable, “prevention” focuses on risk‑reduction and early detection.

• Maintain a healthy weight – lowers estrogen excess from adipose tissue.
• Screen for thyroid disease – routine TSH testing if you have symptoms of hypothyroidism or hyperthyroidism.
• Family history awareness – inform your provider if relatives have fibroids, bleeding disorders, or early menopause.
• Avoid smoking – linked to earlier onset of fibroids and heavier bleeding.
• Regular gynecologic exams – annual pelvic ultrasound for women with known fibroids or polyps can detect growth before it becomes symptomatic.

Complications

If left untreated, menorrhagia can lead to short‑ and long‑term health problems.

• Iron‑deficiency anemia – may cause chronic fatigue, reduced work performance, and in severe cases, heart failure.
• Reduced bone density – chronic anemia and some hormonal treatments (e.g., GnRH agonists) can affect calcium metabolism.
• Infertility – excessive bleeding can disrupt the endometrial environment needed for implantation.
• Psychological impact – depression, social isolation, and diminished sexual satisfaction.
• Emergency hemorrhage – rare but possible, especially with underlying coagulation disorders.

When to Seek Emergency Care

References

1. Mayo Clinic. “Heavy Menstrual Bleeding (Menorrhagia).” https://www.mayoclinic.org.
2. Centers for Disease Control and Prevention. “Menorrhagia.” https://www.cdc.gov.
3. National Institutes of Health. “Uterine Fibroids.” https://www.nichd.nih.gov.
4. World Health Organization. “Guidelines for the Management of Heavy Menstrual Bleeding.” 2022.
5. Cleveland Clinic. “Treatment Options for Heavy Menstrual Bleeding.” https://my.clevelandclinic.org.
6. A. L. C. Hurskainen et al., “Tranexamic Acid versus NSAIDs for Menorrhagia: A Meta‑analysis,” *Obstetrics & Gynecology*, 2021.
7. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 136: “Management of Abnormal Uterine Bleeding.” 2020.

```